Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

Bioabsorbable Stents (BAS) Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update


Summary

GlobalData's Medical Devices sector report, “Bioabsorbable Stents (BAS) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Bioabsorbable Stents (BAS) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Bioabsorbable stents are also known as bioreabsorbable or biodegradable coronary stents. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope
  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
Reasons to Buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date


  • About GlobalData
  • Introduction
    • Bioabsorbable Stents (BAS) Overview
  • Products under Development
    • Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
      • Table Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
    • Bioabsorbable Stents (BAS) - Pipeline Products by Territory
      • Table Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Territory
    • Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
      • Table Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
    • Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
      • Table Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
      • Table Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
    • Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
      • Table Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
      • Table Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
  • Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies
    • Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
      • Table Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
    • Bioabsorbable Stents (BAS) –Companies Pipeline Products by Stage of Development
      • Table Bioabsorbable Stents (BAS) –Companies Pipeline Products by Stage of Development
  • Bioabsorbable Stents (BAS) Companies and Product Overview
    • Abbott Vascular Inc Company Overview
      • Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Second Generation Bioresorbable Vascular Scaffold - Product Status
        • Table Second Generation Bioresorbable Vascular Scaffold - Product Description
    • Amaranth Medical Inc Company Overview
      • Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Amaranth Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table 80-micron MAGNITUDE Bioresorbable Scaffold - Product Status
        • Table 80-micron MAGNITUDE Bioresorbable Scaffold - Product Description
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
        • Table DEFIANCE Scaffold - Product Status
        • Table DEFIANCE Scaffold - Product Description
        • Table FORTITUDE Scaffold - Product Status
        • Table FORTITUDE Scaffold - Product Description
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Status
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Product Description
        • Table Second Generation FORTITUDE Scaffold - Product Status
        • Table Second Generation FORTITUDE Scaffold - Product Description
        • Table Amaranth Medical Inc - Ongoing Clinical Trials Overview
        • Table APTITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
        • Table MAGNITUDE Sirolimus-Eluting Bioresorbable Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
    • Arterius Ltd Company Overview
      • Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
        • Table Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
    • Biosensors International Group Ltd Company Overview
      • Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Sparrow Drug Eluting Stent System - Product Status
        • Table Sparrow Drug Eluting Stent System - Product Description
    • Biosten, LLC Company Overview
      • Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Endovascular Implant - Product Status
        • Table Biodegradable Endovascular Implant - Product Description
    • Biotronik AG Company Overview
      • Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
        • Table DREAMS 3G System - Product Status
        • Table DREAMS 3G System - Product Description
        • Table Magmaris Bioresorbable Magnesium Scaffold - Product Status
        • Table Magmaris Bioresorbable Magnesium Scaffold - Product Description
        • Table Biotronik AG - Ongoing Clinical Trials Overview
        • Table Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
        • Table Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
        • Table Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
        • Table Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
        • Table Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian STsegment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
        • Table Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds Magmaris (MAGIC Registry)
        • Table Magmaris Bioresorbable Magnesium Scaffold - RMS (Resorbable Magnesium Scaffolds) Registry
        • Table Magmaris Bioresorbable Magnesium Scaffold - Scaffold Implantation in Emilia-Romagna
        • Table DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
        • Table DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial
    • Biotronik SE & Co KG Company Overview
      • Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
        • Table AMS-2 - Product Status
        • Table AMS-2 - Product Description
    • Biotyx Medical (Shenzhen) Co Ltd Company Overview
      • Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table IBS Angel - Product Status
        • Table IBS Angel - Product Description
        • Table Biotyx Medical (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
        • Table IBS Angel - A Prospective, Multi-center, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in Patients with Pulmonary Artery Stenosis
    • Boston Scientific Corp Company Overview
      • Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fully Resorbable Drug-Eluting Scaffold System - Product Status
        • Table Fully Resorbable Drug-Eluting Scaffold System - Product Description
        • Table Synergy Megatron Bioabsorbable Polymer (BP) Stent - Product Status
        • Table Synergy Megatron Bioabsorbable Polymer (BP) Stent - Product Description
        • Table Boston Scientific Corp - Ongoing Clinical Trials Overview
        • Table Synergy Megatron Bioabsorbable Polymer (BP) Stent - A U.S. Post-Approval Study of the SYNERGYTM Everolimus- Eluting Platinum Chromium Coronary Stent System Evaluating the SYNERGY XLV (MEGATRON) Stent System
    • Cardionovum GmbH Company Overview
      • Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cardiosorb - Product Status
        • Table Cardiosorb - Product Description
    • Cordis Corp Company Overview
      • Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table SymBio Pimecrolimus/Paclitaxel-Eluting Stent - Product Status
        • Table SymBio Pimecrolimus/Paclitaxel-Eluting Stent - Product Description
    • HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
      • HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Xinsorb BRS - Product Status
        • Table Xinsorb BRS - Product Description
    • Icon Interventional Systems, Inc. Company Overview
      • Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biosorb Pediatric Dissolving Stent - Product Status
        • Table Biosorb Pediatric Dissolving Stent - Product Description
    • Japan Stent Technology Co., Ltd. Company Overview
      • Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioabsorbable Stent - Product Status(Japan Stent Technology Co., Ltd)
        • Table Bioabsorbable Stent - Product Description(Japan Stent Technology Co., Ltd)
    • Kyoto Medical Planning Co Ltd Company Overview
      • Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Kyoto Medical Planning Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Igaki-Tamai Coronary Stent - Product Status
        • Table Igaki-Tamai Coronary Stent - Product Description
    • Lifetech Scientific (Shenzhen) Co Ltd Company Overview
      • Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Lifetech Scientific (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Product Status
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Product Description
        • Table Lifetech Scientific (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A First-in-man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Multi-center, Single-arm Trial of the Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-III
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - A Prospective, Non-randomized, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System
        • Table IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System - Feasibility, Efficacy and Safety of IBS for Implantation in the PDA in Duct-dependent Cyanotic CHD
    • Manli Cardiology Ltd Company Overview
      • Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Manli Cardiology Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Mirage - Product Status
        • Table Mirage - Product Description
    • Meril Life Sciences Pvt Ltd Company Overview
      • Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Meril Life Sciences Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table MeRes100 - Product Status
        • Table MeRes100 - Product Description
        • Table Meriskin BRS - Product Status
        • Table Meriskin BRS - Product Description
        • Table Meril Life Sciences Pvt Ltd - Ongoing Clinical Trials Overview
        • Table MeRes100 - A Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in Treatment of Coronary Artery Disease Patients: MeRes - China
        • Table MeRes100 - A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions: MeRes-1 Extend
        • Table MeRes100 - To Compare the Safety and Performance of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions
    • Micell Technologies Inc Company Overview
      • Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Micell Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioresorbable Scaffold (BRS) - Product Status
        • Table Bioresorbable Scaffold (BRS) - Product Description
    • Michigan Technological University Company Overview
      • Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Michigan Technological University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioabsorbable Stent - Product Status(Michigan Technological University)
        • Table Bioabsorbable Stent - Product Description(Michigan Technological University)
    • MicroPort Scientific Corp Company Overview
      • MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table MicroPort Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
        • Table Firefalcon Bioresorbable Device - Product Status
        • Table Firefalcon Bioresorbable Device - Product Description
        • Table Firesorb Bioresorbable Scaffold - Product Status
        • Table Firesorb Bioresorbable Scaffold - Product Description
        • Table MicroPort Scientific Corp - Ongoing Clinical Trials Overview
        • Table Firesorb Bioresorbable Scaffold - A First-in-man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-I
        • Table Firesorb Bioresorbable Scaffold - A Prospective Multicenter Single-arm Clinical Trial Assessing the Safety and Effectiveness of Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold for the Treatment of Coronary Artery Disease: FUTURE III
        • Table Firesorb Bioresorbable Scaffold - A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients with Coronary Artery Disease: FUTURE-II
    • Minvasys SAS Company Overview
      • Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table Minvasys SAS Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Status
        • Table Nile LM SIR Sirolimus Eluting Intracoronary Stent - Product Description
    • MIV Therapeutics Inc Company Overview
      • MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Smart-1 DES - Product Status
        • Table Smart-1 DES - Product Description
        • Table Smart-4 DES - Product Status
        • Table Smart-4 DES - Product Description
        • Table VESTAsync - Product Status
        • Table VESTAsync - Product Description
    • NanoCoeur, Inc. Company Overview
      • NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanocoating Cardiac Stent - Product Status
        • Table Nanocoating Cardiac Stent - Product Description
    • North Carolina State University Company Overview
      • North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
        • Table North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Metal Stent - Product Status
        • Table Biodegradable Metal Stent - Product Description
    • Northwestern University Company Overview
      • Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
        • Table Liquid Cast Drug-Eluting Biodegradable Stent - Product Status
        • Table Liquid Cast Drug-Eluting Biodegradable Stent - Product Description
    • OrbusNeich Company Overview
      • OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
        • Table OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
        • Table Cura Stent - Product Status
        • Table Cura Stent - Product Description
        • Table Sirolimus-Eluting Absorbable Vascular Scaffold - Product Status
        • Table Sirolimus-Eluting Absorbable Vascular Scaffold - Product Description
    • Pediastent LLC Company Overview
      • Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pediastent LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Pediatric Bioresorbable Stent - Product Status
        • Table Pediatric Bioresorbable Stent - Product Description
    • QualiMed Innovative Medizinprodukte GmbH Company Overview
      • QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table QualiMed Innovative Medizinprodukte GmbH Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Coronary Stent - Product Status
        • Table Biodegradable Coronary Stent - Product Description
    • REVA Medical Inc Company Overview
      • REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table REVA Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Status
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Product Description
        • Table REVA Medical Inc - Ongoing Clinical Trials Overview
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Expanded FANTOM II Clinical Study
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Post Market Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety and Efficacy of the FANTOM ENCORE Sirolimuseluting Bioresorbable Scaffold for Treatment of De-novo Coronary Artery Disease: The ENCORE-I Study
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Safety and Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
        • Table Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold - Vascular Healing Pattern, Vasoreactivity, and Quality of Life in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention with Sirolimus Eluting FANTOM Bioresorbable Vascular Scaffold with Long Term Clinical, Near Infrared Spectroscopy and Optical Coherence Tomography Follow-up: A FANTOM STEMI Pilot Study
    • S3V Vascular Technologies Company Overview
      • S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
        • Table S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
        • Table 3V Avatar - Product Status
        • Table 3V Avatar - Product Description
    • Shanghai Bio-heart Biological Technology Co Ltd Company Overview
      • Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Shanghai Bio-heart Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Bioheart BRS System - Product Status
        • Table Bioheart BRS System - Product Description
        • Table Bioheart Ultra BRS System - Product Status
        • Table Bioheart Ultra BRS System - Product Description
        • Table Shanghai Bio-heart Biological Technology Co Ltd - Ongoing Clinical Trials Overview
        • Table Bioheart BRS System - A Randomized Controlled Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II
        • Table Bioheart BRS System - A Registry Trial of the Bioheart Rapamycin Drug-eluting Bioresorbable Coronary Stent System in Patients with Coronary Artery Disease: BIOHEART III
        • Table Bioheart BRS System - Study of Bioheart BRS System for the Treatment of Coronary Artery Disease
    • Shanghai Healing Medical Instruments Co Ltd Company Overview
      • Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Shanghai Healing Medical Instruments Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
        • Table Biodegradable Sinus Stent - Product Status
        • Table Biodegradable Sinus Stent - Product Description
    • Tepha Inc Company Overview
      • Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table Tepha Inc Pipeline Products & Ongoing Clinical Trials Overview
        • Table TephaFLEX Absorbable Coronary Stent - Product Status
        • Table TephaFLEX Absorbable Coronary Stent - Product Description
    • Tremedics Medical Devices LLC Company Overview
      • Tremedics Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Tremedics Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview
        • Table Illusicor - Product Status
        • Table Illusicor - Product Description
    • UAB Minority Health and Health Equity Research Center Company Overview
      • UAB Minority Health and Health Equity Research Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table UAB Minority Health and Health Equity Research Center Pipeline Products & Ongoing Clinical Trials Overview
        • Table Endothelium Nanomatrix Coated Stent - Product Status
        • Table Endothelium Nanomatrix Coated Stent - Product Description
    • University of Florida Company Overview
      • University of Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Florida Pipeline Products & Ongoing Clinical Trials Overview
        • Table Nanocomposite Drug Eluting Stent - Product Status
        • Table Nanocomposite Drug Eluting Stent - Product Description
    • University of Strathclyde Company Overview
      • University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table University of Strathclyde Pipeline Products & Ongoing Clinical Trials Overview
        • Table Magnesium Alloy Stent - Product Status
        • Table Magnesium Alloy Stent - Product Description
    • VasoTech Inc. Company Overview
      • VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
        • Table PowerStent Absorb DES - Product Status
        • Table PowerStent Absorb DES - Product Description
    • Xenogenics Corporation Company Overview
      • Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
        • Table Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
        • Table Ideal BioStent - First Generation - Product Status
        • Table Ideal BioStent - First Generation - Product Description
        • Table Ideal BioStent - Second Generation - Product Status
        • Table Ideal BioStent - Second Generation - Product Description
        • Table Whisper Coronary Stent System - Product Status
        • Table Whisper Coronary Stent System - Product Description
  • Bioabsorbable Stents (BAS)- Recent Developments
    • Mar 08, 2023: OrbusNeich Announces Record Revenue of US$136.8 Million, Adjusted Net Profit Up 25% to US$26.7 Million
    • Feb 09, 2023: Terumo Notice Concerning Revision of the Full-Year Financial Guidance for Fiscal Year Ending March 31, 2023
    • Feb 09, 2023: Terumo Corp Announces Consolidated Financial Results for the Third Quarter Ended December 31, 2022
    • Nov 10, 2022: Terumo Corp Announces Consolidated Financial Results for the Second Quarter Ended September 30, 2022
    • Aug 16, 2022: Boston Scientific Announces Upcoming Conference Schedule
    • Apr 28, 2022: Boston Scientific reports net sales of $3.03bn in Q1 2022
    • Apr 27, 2022: Boston Scientific Announces Results for First Quarter 2022
  • Appendix
    • Methodology
      • Table Glossary
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings